Legal Representation
Attorney
Kristen S. Ruisi
USPTO Deadlines
Next Deadline
14 days remaining
Published for Opposition
Due Date
January 01, 2026
Extension Available
Until February 01, 2026
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 2, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 2, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 26, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 4, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 8, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 30, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 30, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 10, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jul 9, 2025 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Jun 27, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jun 27, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Mar 30, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 30, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 30, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 30, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 30, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 30, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 13, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
Class 040
Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
Class 042
Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; scientific research in the nature of conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design
Class 044
Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice
Additional Information
Design Mark
The mark consists of the word BEONE in stylized form to the right of a shaded square with a stylized square and a star in the center of the stylized square.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
BE ONE; BE 1
Classification
International Classes
005
040
042
044